Skip to main content

Table 1 Carbapenem non-susceptibility of K. pneumoniae isolates in Germany 2011–2016 (n = 154,734)

From: Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)

Tested carbapenem Number of isolates tested (% of all isolates) Isolates tested “susceptible” (% with 95% CI)a Isolates tested “intermediate” (% with 95% CI)a Isolates tested “resistant” (% with 95% CI)a Isolates tested “non-susceptible” (% with 95% CI)a
Meropenem 150,746 (97.4%) 99.58% (99.49, 99.65%) 0.09% (0.07, 0.12%) 0.33% (0.27, 0.40%) 0.42% (0.35, 0.51%)
Imipenem 150,114 (97.0%) 99.62% (99.54, 99.69%) 0.11% (0.09, 0.14%) 0.27% (0.22, 0.34%) 0.38% (0.31, 0.46%)
Ertapenem 56,560 (36.6%) 98.95% (98.68, 99.16%) 0.11% (0.08, 0.16%) 0.94% (0.74, 1.2%) 1.05% (0.84, 1.32%)
At least one carbapenemb 154,524 (99.9%) 99.37% (99.24, 99.49%) 0.11% (0.08, 0.13%) 0.52% (0.42, 0.64%) 0.63% (0.51, 0.76%)
  1. a 95% CI calculated accounting for clustering on hospital level
  2. bMeropenem, imipenem or ertapenem